Ventrus Biosciences Cash Flow - Quarterly (NASDAQ:ASMB)

Add to My Stocks
$44.18 $1.53 (3.35%) ASMB stock closing price Jun 22, 2018 (Closing)

The Ventrus Biosciences cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Ventrus Biosciences profits and Ventrus Biosciences debt. Ventrus Biosciences saw a cash impact of $1.49M from the issuance of ASMB shares. The cash flow statement helps in the Ventrus Biosciences stock analysis by providing more information for evaluating changes in assets, liabilities and equities. Ventrus Biosciences had an outflow of $-15.5M from operating activities, $1.49M inflow due to financing activities, and $-1.1M outflow due to investing activities till 2018 Q1.

View and download details of Ventrus Biosciences cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-3.43M44.36M45M46.38M47.48M3.75M4.17M1.8M-1.78M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net4.01M-6.3M3.64M1.36M5.54M4.64M3.32M1.66M7.9M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.03M-0.86M-0.5M---0.14M-0.03M---0.05M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-1.06M-14.77M-13.46M-12.45M6.65M36.34M20.56M9.21M2.5M-64.79M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares1.49M67.24M1.01M------81.56M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year28.57M27.1M29.09M27.06M20.48M36.97M14.57M---
Cash & Equivalents at Year End66.92M82.03M27.24M39.45M70.81M28.57M23.79M20.34M20.39M27.1M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Ventrus Biosciences stock price history provides the price history of a stock, Ventrus Biosciences stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Ventrus Biosciences has cash of $66.92M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Ventrus Biosciences stock price.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Ventrus Biosciences lost $-15.5M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash from investing stood at a negative value of $-1.1M for ASMB stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Ventrus Biosciences earned $1.49M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Ventrus Biosciences Cash Flow

Quarterly Cash Flow Statements For Assembly Biosciences Inc Peers

Chimerix cash flow, Celator Pharma cash flow, CytoDyn cash flow, Paratek Pharma cash flow